Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18
inhaled drug delivery
Biotech
Enterprise posts CF win, succeeding where Big Pharma stumbled
The phase 2 trial hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.
Nick Paul Taylor
May 12, 2026 4:00am
Vistagen's social anxiety disorder asset stumbles in phase 3
Dec 17, 2025 2:44pm
Fierce Pharma
Avalyn adds $100M to advance inhaled versions of IPF pills
Jul 22, 2025 10:44am
Synairgen ACTIV-2 trial paused while NIH tweaks study design
Mar 3, 2022 3:30pm
Synairgen's COVID-19 SPRINTER trial falls at final hurdle
Feb 22, 2022 7:05am
Inhalable antibody tamps down COVID-19 in hamsters
Oct 15, 2021 8:50am
